Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector
March 04 2021 - 3:00AM
Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life
science reagents and tools, announced the expansion of its
footprint in China with the opening of new custom-built facilities
in Hangzhou and Shanghai. Expanded customer service, logistics and
manufacturing capabilities are strengthening Abcam’s position as a
leading collaborator for academia and industry in the region.
Alan Hirzel, CEO, Abcam, said:
“Over the 15 years Abcam has been active in China, we have been
focused on working closely with scientists to help them accelerate
their discoveries and have an impact on society in China and
beyond. These facilities represent another step in our growth
and, more importantly, allow us to support the growth and
importance of Chinese science and its contribution to global
wellbeing.”
The size of the Hangzhou facility has been
increased by a third to meet the needs of strategic partners and
customers focused on research, therapeutic, and in vitro diagnostic
applications. With new automation and technology, fully flexible
laboratory configurations and a specially designed logistics hub,
the facility is driving the growth of Abcam’s high-quality,
validated reagent portfolio. In addition, the new 10,000 sq ft
Shanghai location is facilitating Abcam’s direct customer support
across the region.
Jade Zhang, General Manager (Marketing)
in China, Abcam, commented: “Last year has highlighted the
importance of collaboration in delivering scientific breakthroughs.
As we continue to anticipate the needs of Chinese scientists, we
are excited to be expanding our capabilities and capacity to
deliver the products and services required. This expansion also
supports our world-class team and provides an inspiring work
environment fostering our culture of innovation and
collaboration.”
Abcam continues to strengthen its presence in
the region through strategic partnerships and collaborations with
key industry players. In January 2021 Abcam expanded its long-term
strategic alliance with Shuwen Biotech, a leading Chinese company
focusing on the development and commercialization of companion
diagnostics for both China and ex-China.
The footprint expansion in China is an integral
part of the Company’s commitment to sustainably deliver
high-quality reproducible reagents to the global life science
community.
Notes to Editors
About Abcam plc
As a global life sciences company, Abcam
identifies, develops, and distributes high-quality biological
reagents and tools that are crucial to research, drug discovery and
diagnostics. Working across the industry, the Company supports life
scientists to achieve their mission, faster.
Abcam partners with life science organizations
to co-create novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays,
Abcam is helping advance the global understanding of biology and
causes of disease, which enables new treatments and improved
health. The Company's pioneering data-sharing approach gives
scientists increased confidence in their results by providing
validation, user comments and peer-reviewed citations for its
110,000 products.
With 13 sites globally, many of Abcam's
1,500-strong team are located in the world's leading life science
research hubs, complementing a global network of services and
support.
To find out more, please
visit www.abcam.com and www.abcamplc.com.
For media queries, contact:
Dr Lynne Trowbridge
VP External Communications
T: +44 (0)7815 167026
E: external.comms@abcam.com
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Apr 2023 to Apr 2024